Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis

Women's Health

Volumn 6, Issue 1, 2010, Pages 27-35

  Harada, Tasuku ^a   Taniguchi, Fuminori ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

endometriosis; irregular bleeding; levonogestrel releasing intrauterine system; oral progestin; progesterone receptor

Indexed keywords

DIENOGEST; DRUG DERIVATIVE; HORMONE ANTAGONIST; NANDROLONE;

ANIMAL; DRUG EFFECT; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE; HUMAN; MALE; OVARY; RABBIT; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; UTERUS BLEEDING;

ANIMALS; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE; HORMONE ANTAGONISTS; HUMANS; MALE; NANDROLONE; OVARY; RABBITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UTERINE HEMORRHAGE;

EID: 77951220948     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/WHE.09.72     Document Type: Article

References (40)

1. Papers of special note have been highlighted as:
2. of interest
3. of considerable interest
4. Child TJ Tan SL: Endometriosis: aetiology, pathogenesis and treatment. Drugs 61: 1735–1750 (2001).
5. Marques A Bahamondes L Aldrighi JM Petta CA: Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire. J. Reprod. Med. 49, 115–120 (2004).
6. Momoeda M Taketani Y Terakawa N et al.: Is endometriosis really associated with pain? Gynecol. Obstet. Invest. 54(Suppl. 1), 18–23 (2002).
7. Olive DL Pritts EA: Treatment of endometriosis. N. Engl. J. Med. 345, 266–275 (2001).
8. Crosignani PG Olive D Bergqvist A Luciano A: Advances in the management of endometriosis: an update for clinicians. Hum. Reprod. Update 12, 179–189 (2006).
9. Petta CA Ferriani RA Abrao MS et al.: Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum. Reprod. 20, 1993–1998 (2005).
10. Vercellini P Frontino G Giorgi OD Aimi G Zaina B Crosignani PG: Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil. Steril. 80, 305–309 (2003).
11. Foster RH Wilde MI: Dienogest. Drugs 56, 825–833 (1998).
12. Moore C Carol W Graser T Mellinger U Walter F: Influence of dienogest on ovulation in young fertile women. Clin. Drug Invest. 18, 271–278 (1999).
13. Okada H Nakajima T Yoshimura T Yasuda K Kanzaki H: The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol. Hum. Reprod. 7, 341–347 (2001).
14. Direct inhibitory effects of dienogest (DNG) on endometriotic cells was described.
15. Horie S Harada T Mitsunari M Taniguchi F Iwabe T Terakawa N: Progesterone and progestational compounds attenuate tumor necrosis factor α-induced interleukin-8 production via nuclear factor kB inactivation in endometriotic stromal cells. Fertil. Steril. 83, 1530–1535 (2005).
16. Mechanism of DNG action on cytokine production was reported.
17. Moore C Kohler G Muller A: The treatment of endometriosis with dienogest. Drugs Today 35(Suppl. C), 41–52 (1999).
18. Results of a dose-dependency study in Europe were presented.
19. Hubner M Ponsold K: The synthetic approach to STS 557 - structure activity relationships in 17 α-CH2X-substituted 19-nortestosterone derivatives. Exp. Clin. Endocrinol. 81, 109–114 (1983).
20. Juchem M Schaffrath M Pollow G Hoffmann G Kaufmann G: Dienogest: bidungsstudien an verschiedenen rezeptor und serumproteinen. In: Dienogest – Praklinik und Klinik eines neuen Gestagens. Teichmann AT (Ed.). Walter de Gruyter, Berlin, Germany & NY, USA, 119–133 (1995).
21. Sasagawa S Shimizu Y Kami H et al.: Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 73, 222–231 (2008).
22. Oettel M Carol W Elger W et al.: A 19-norprogestin without a 17α-ethinyl group II: dienogest from a pharmacokinetic point of view. Drugs Today 31, 517–536 (1995).
23. Oettel M Elger W Ernst M et al.: Experimentelle Endokrinpharmackologie von Dienogest. In: Dienogest – Praeklinik und Klinik eines neuen Gestagens. Teichmann AT (Ed.). Walter de Gruyter, Berlin, Germany & NY, USA, 11–21 (1995).
24. Katsuki Y Sasagawa S Takano Y et al.: Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid. Drugs Exp. Clin. Res. 23, 45–62 (1997).
25. Moore C Carol W Graser T Mellinger U Walter F: Influence of dienogest on ovulation in young fertile women. Clin. Drug Invest. 18, 271–278 (1999).
26. Schleussner E Miichels E Bethge W Klinger G: Die Wirkung von Dienogest auf die hypothalamisch-hypophysare Achse: Ergebnisse einer Pilotstudie.In: Dienogest – Praklinik und Klinik eines neuen Gestagens. Teichmann AT (Ed.). Walter de Gruyter, Berlin, Germany & NY, USA, 171–179 (1995).
27. Sasagawa S Shimizu Y Nagaoka T Tokado H Imada K Mizuguchi K: Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys. J. Endocrinol. Invest. 31, 636–641 (2008).
28. Fu L Osuga Y Morimoto C et al.: Dienogest inhibits BrdU uptake with G (0)/G(1) arrest in cultured endometriotic stromal cells. Fertil. Steril. 89(5) 1344–1347 (2007).
29. Tsuno A Nasu K Yuge A Matsumoto H Nishida M Narahara H: Decidualization attenuates the contractility of eutopic and ectopic endometrial stromal cells: implications for hormone therapy of endometriosis. J. Clin. Endocrinol. Metab. 94(7), 2516–2523 (2009).
30. Katsuki Y Shibutani Y Aoki D Nozawa S: Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 79, 169–176 (1997).
31. Nakamura M Katsuki Y Shibutani Y Oikawa T: Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur. J. Pharmacol. 386, 33–40 (1999).
32. Tatsumi H Kitawaki J Tanaka K Hosoda T Honjo H: Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins. Maturitas 42, 287–294 (2002).
33. Golbs S Reimann I Zimmermann H et al.: Gestagen Dienogest: Bei der kombiniert-hormonalen Kontrazeption ist die Pharmakokinetik des Gestagens ausschlaggebend. Gynako-Endocrinologie 3, 25–32 (1995).
34. Oettel M Bervoas-Martin S Elger W et al.: A 19-norprogestin without a 17α-ethinyl group I: dienogest from a pharmacokinetic point of view. Drugs Today 31, 499–516 (1995).
35. Schindler A Christensen B Henkel A Oettel M Moore C: High-dose pilot study with the novel progestogen dienogest in patients with endometriosis. Gynecol. Endocrinol. 22, 9–17 (2006).
36. Clinical trial of a high-dose DNG study.
37. Cosson M Querleu D Donnez J et al.: Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil. Steril. 77, 684–692 (2002).
38. Clinical trial of DNG versus triptorelin.
39. Harada T Momoeda M Taketani Y et al.: Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis-α randomized, double-blind, multi center, controlled trial. Fertil. Steril. 91, 675–681 (2009).
40. Clinical trial of DNG versus buserelin in a Japanese Phase III study.